Decoding the Intricacies of Statin-Associated Muscle Symptoms

Purpose of Review: Hyperlipidemia is the major cardiovascular morbidity and mortality risk factor. Statins are the first-line treatment for hyperlipidemia. Statin-associated muscle symptoms (SAMS) are the main reason for the discontinuation of statins among patients. The purpose of this review is to guide clinicians to recognize the difference between self-limited and autoimmune statin myopathy in addition to the factors that potentiate them. Finally, treatment strategies will be discussed. This review mostly focuses on new data in the past 3 years. Recent Findings: Recent findings suggest that SAMS is a complex and multifactorial condition that involves mitochondrial dysfunction, oxidative stress, and immune-mediated mechanisms. Effective management of SAMS requires a thorough evaluation of the patient’s symptoms, risk factors, and medication history, as well as consideration of alternative treatment options. Summary: While statins are effective in reducing the risk of cardiovascular events, their use is associated with a range of adverse effects, including SAMS.